A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

To join this study, you must have been diagnosed with non-small cell lung cancer that is considered 'early stage' (Stage IIB to IIIB) and can be removed by surgery. Your doctors will check if your cancer falls into these categories based on its size and if it has spread to nearby lymph nodes.

You would also need to have certain test results, including having no specific genetic changes (like EGFR or ALK mutations) in your cancer cells. Doctors will perform tests to check your overall health, including your heart, lungs, and liver, to make sure it's safe for you to take part. Your general fitness level must be good, and you need to be at least 18 years old.

There are also specific blood test results needed to confirm your blood cells, kidney, and liver are working well enough. If you are a woman who could become pregnant, you would need to have a negative pregnancy test.

If you decide to take part, you will first receive chemotherapy combined with durvalumab, followed by surgery. After your surgery, if some cancer cells were found, you will then be randomly assigned to one of two groups. One group will receive durvalumab injections every four weeks for a year, and the other group will be closely monitored without receiving this extra treatment.

You will have regular hospital visits for check-ups, blood tests, and scans to monitor your health and how you are responding to treatment. The exact number and frequency of visits will be explained by the study team, but throughout the entire process, including follow-up, the study could last for several years.